Marcy l’Étoile, France, November 3, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ending September 30, 2026.
Key highlights:
- Solid performance in Q3 2026 with +8% organic sales growth.
- +13% organic sales growth across the GO•28 strategic plan growth drivers.
- Confirmation of the 2026 guidance.
- Sales grew organically by 2.7% in the first nine months of 2026, reaching €3,006m, driven by strong growth in BIOFIRE® non-respiratory panels (+12%), SPOTFIRE® range (+21% despite lower respiratory activity than in 2025), clinical microbiology (+6%), and Industrial Applications (+8%). Sales of BIOFIRE® respiratory panels decreased by 14%, reflecting significantly lower respiratory epidemiological activity than in the same period of 2025.
- Q3 2026 sales totaled €1,042 million, delivering solid organic growth of 8%, driven by a 13% increase in sales from GO•28 growth drivers. The SPOTFIRE® platform continued to expand strongly, with more than 900 new installations during the quarter.
Pierre Boulud, Chief Executive Officer, stated: “The Group delivered a strong performance in the third quarter of 2026, reflecting the contribution of the GO•28 four growth drivers. During the period, bioMérieux also strengthened its point-of-care offering with the launch of the high-sensitivity troponin I assay on the SPINCHIP® platform in Europe and the dual FDA clearance / CLIA waiver of the BIOFIRE® SPOTFIRE® Vaginitis Panel.”
Read the full press release
- Filename
- bioMerieux-PR-Q3-sales-2026.pdf
- Size
- 442 KB
- Format
- application/pdf